Skip to Content

Ustekinumab

Medically reviewed by Drugs.com. Last updated on Aug 21, 2020.

Pronunciation

(yoo stek in YOO mab)

Index Terms

  • CNTO 1275

Dosage Forms

Excipient information presented when available (limited, particularly for generics); consult specific product labeling.

Solution, Intravenous:

Stelara: 130 mg/26 mL (26 mL) [contains edetate (edta) disodium dihydrate, polysorbate 80]

Solution, Subcutaneous [preservative free]:

Stelara: 45 mg/0.5 mL (0.5 mL) [contains polysorbate 80]

Solution Prefilled Syringe, Subcutaneous [preservative free]:

Stelara: 45 mg/0.5 mL (0.5 mL); 90 mg/mL (1 mL) [contains polysorbate 80]

Brand Names: U.S.

  • Stelara

Pharmacologic Category

  • Antipsoriatic Agent
  • Interleukin-12 Inhibitor
  • Interleukin-23 Inhibitor
  • Monoclonal Antibody

Pharmacology

Ustekinumab is a human monoclonal antibody that binds to and interferes with the proinflammatory cytokines, interleukin (IL)-12 and IL-23. Biological effects of IL-12 and IL-23 include natural killer (NK) cell activation, CD4+ T-cell differentiation and activation. Ustekinumab also interferes with the expression of monocyte chemotactic protein-1 (MCP-1), tumor necrosis factor-alpha (TNF-α), interferon-inducible protein-10 (IP-10), and interleukin-8 (IL-8). Significant clinical improvement in psoriasis and psoriatic arthritis patients is seen in association with reduction of these proinflammatory signalers.

Distribution

Crohn disease: Vd (central compartment): 2.7 L; Vdss: 4.6 L.

Ulcerative colitis: Vd (central compartment): 3 L; Vdss: 4.4 L.

Time to Peak

Psoriasis: SubQ: Plasma: 45 mg: 13.5 days; 90 mg: 7 days.

Half-Life Elimination

SubQ:

Crohn disease, ulcerative colitis: Terminal: ~19 days.

Psoriasis: 14.9 ± 4.6 to 45.6 ± 80.2 days.

Special Populations Note

Body weight: When given the same dose, subjects weighing >100 kg had lower median serum concentrations compared with those subjects weighing ≤100 kg. The median trough serum concentrations of ustekinumab in subjects >100 kg in the 90 mg group were comparable with those in subjects ≤100 kg in the 45 mg group.

Use: Labeled Indications

Crohn disease: Treatment of moderately to severely active Crohn disease in adults.

Plaque psoriasis: Treatment of moderate to severe plaque psoriasis in patients ≥6 years of age who are candidates for phototherapy or systemic therapy.

Psoriatic arthritis: Treatment of active psoriatic arthritis (as monotherapy or in combination with methotrexate) in adults.

Ulcerative colitis: Treatment of moderately to severely active ulcerative colitis in adults.

Contraindications

Clinically significant hypersensitivity to ustekinumab or any component of the formulation

Canadian labeling: Additional contraindications (not in the US labeling): Severe infections such as sepsis, tuberculosis, and opportunistic infections

Dosing: Adult

Crohn disease:

Induction: IV:

≤55 kg: 260 mg as single dose

>55 kg to 85 kg: 390 mg as single dose

>85 kg: 520 mg as single dose

Maintenance: SubQ: 90 mg every 8 weeks; begin maintenance dosing 8 weeks after the IV induction dose.

Plaque psoriasis: SubQ:

Initial and maintenance:

≤100 kg: 45 mg at 0 and 4 weeks, and then every 12 weeks thereafter

>100 kg: 90 mg at 0 and 4 weeks, and then every 12 weeks thereafter. Note: Doses of 45 mg given to patients >100 kg were also efficacious; however, 90 mg is the recommended dose in these patients due to greater efficacy.

Psoriatic arthritis: SubQ: Note: When used for psoriatic arthritis, may be administered alone or in combination with methotrexate.

Initial and maintenance: 45 mg at 0 and 4 weeks, and then every 12 weeks thereafter.

Coexistent psoriatic arthritis and moderate to severe plaque psoriasis in patients >100 kg: Initial and maintenance: 90 mg at 0 and 4 weeks, and then every 12 weeks thereafter.

Ulcerative colitis:

Induction: IV:

≤55 kg: 260 mg as single dose.

>55 kg to 85 kg: 390 mg as single dose.

>85 kg: 520 mg as single dose.

Maintenance: SubQ: 90 mg every 8 weeks; begin maintenance dosing 8 weeks after the IV induction dose.

Dosing: Geriatric

Refer to adult dosing.

Dosing: Pediatric

Note: Dosing presented in mg/kg and fixed mg; use extra precaution to ensure dosing units.

Plaque psoriasis, moderate to severe: Children ≥6 years and Adolescents:

<60 kg: SubQ: Initial: 0.75 mg/kg at 0 and 4 weeks, followed by maintenance dose of 0.75 mg/kg every 12 weeks.

≥60 to ≤100 kg: SubQ: Initial: 45 mg at 0 and 4 weeks, followed by maintenance dose of 45 mg every 12 weeks.

>100 kg: SubQ: Initial: 90 mg at 0 and 4 weeks, followed by maintenance dose of 90 mg every 12 weeks.

Inflammatory bowel disease, moderate to severe; refractory: Limited data available (Bishop 2016; Dayan 2019): Note: Dosing varies by route of administration (IV or SubQ); use extra precaution.

Children ≥12 years and Adolescents:

Induction: IV:

<55 kg: 260 mg as single dose.

≥55 to 85 kg: 390 mg as single dose.

>85 kg: 520 mg as single dose.

Maintenance: SubQ: 90 mg every 8 weeks; begin maintenance dosing 8 weeks after the IV induction dose.

Dosing based on retrospective studies and case reports. A retrospective study of 52 adolescent and young adult (<21 years) patients (median: 16.8 years; 38 patients <18 years of age) diagnosed with inflammatory bowel disease (n=42 Crohn disease; n=10 ulcerative colitis or unspecified) with a majority (81%) having failed previous tumor necrosis factor (TNF)-modulator therapy, utilized a single-dose weight-based IV induction protocol of ustekinumab in most patients (47/52, 90%); the other subjects (5) received subcutaneous induction prior to availability of IV product. Following induction, all patients received fixed dose (regardless of weight) SubQ maintenance therapy (90 mg every 8 weeks). Results showed at the end of 52 weeks, 58% of patients had achieved steroid-free remission and 65% had achieved clinical remission. At week 52, of the 39 patients who continued on ustekinumab, 62% of patients required dosing every 4 to 7 weeks to maintain remission (Dayan 2019). In a retrospective case series, 4 patients (ages 12 to 17 years) who had failed or unable to tolerate previous TNF modifiers received subcutaneous induction doses of 90 mg every 4 weeks for 2 doses, followed by 90 mg every 8 weeks. Two patients were able to wean off steroid regimens and had clinical improvement and 2 patients were unresponsive to therapy (Bishop 2016).

Reconstitution

IV: After calculating the appropriate dosage and volume of ustekinumab (using 130 mg per 26 mL vials), withdraw an equal volume of fluid from 250 mL bag of NS or ½ NS and discard. Add ustekinumab to the NS or ½ NS bag; final volume of bag should be 250 mL. Gently mix bag.

Administration

IV: Infuse over at least 1 hour; use of IV set with an in-line, low-protein binding filter (0.2 micrometer) required. Do not infuse concomitantly in the same IV line with other agents.

Subcutaneous: Administer by subcutaneous injection into the top of the thigh, abdomen, upper arms, or buttocks. Rotate sites. Do not inject into tender, bruised, erythematous, or indurated skin. Avoid areas of skin where psoriasis is present. Discard any unused portion. Intended for use under supervision of physician; self-injection may occur after proper training. If using the single-dose vial, a 1 mL syringe with a 27-gauge 1/2 inch needle is recommended.

Storage

Store intact vials and prefilled syringes at 2°C to 8°C (36°F to 46°F); do not freeze. Store vials upright in the original carton to protect from light until the time of use. Do not shake. Discard any unused portion. Individual prefilled syringes may be stored at room temperature (<30°C [<86°F]) for ≤30 days in the original carton to protect from light; once stored at room temperature, syringe should not be returned to the refrigerator and discarded if not used within 30 days. Diluted solution for infusion may be stored up to 7 hours at room temperature (up to 25°C [77°F]). Infusion should be completed within 8 hours of preparation (including the storage and infusion times); do not freeze diluted solutions.

Drug Interactions

Baricitinib: Immunosuppressants may enhance the immunosuppressive effect of Baricitinib. Management: Use of baricitinib in combination with potent immunosuppressants such as azathioprine or cyclosporine is not recommended. Concurrent use with antirheumatic doses of methotrexate or nonbiologic disease modifying antirheumatic drugs (DMARDs) is permitted. Consider therapy modification

BCG (Intravesical): Immunosuppressants may diminish the therapeutic effect of BCG (Intravesical). Avoid combination

Belimumab: May enhance the immunosuppressive effect of Biologic Anti-Psoriasis Agents. Avoid combination

Cladribine: May enhance the immunosuppressive effect of Immunosuppressants. Avoid combination

Coccidioides immitis Skin Test: Immunosuppressants may diminish the diagnostic effect of Coccidioides immitis Skin Test. Monitor therapy

Denosumab: May enhance the adverse/toxic effect of Immunosuppressants. Specifically, the risk for serious infections may be increased. Monitor therapy

Echinacea: May diminish the therapeutic effect of Immunosuppressants. Management: Consider avoiding Echinacea in patients receiving therapeutic immunosuppressants. If coadministered, monitor for reduced efficacy of the immunosuppressant during concomitant use. Consider therapy modification

Fingolimod: Immunosuppressants may enhance the immunosuppressive effect of Fingolimod. Management: Avoid the concomitant use of fingolimod and other immunosuppressants when possible. If combined, monitor patients closely for additive immunosuppressant effects (eg, infections). Consider therapy modification

Inebilizumab: May enhance the immunosuppressive effect of Immunosuppressants. Monitor therapy

InFLIXimab: May enhance the immunosuppressive effect of Biologic Anti-Psoriasis Agents. Avoid combination

Leflunomide: Immunosuppressants may enhance the adverse/toxic effect of Leflunomide. Specifically, the risk for hematologic toxicity such as pancytopenia, agranulocytosis, and/or thrombocytopenia may be increased. Management: Consider not using a leflunomide loading dose in patients receiving other immunosuppressants. Patients receiving both leflunomide and another immunosuppressant should be monitored for bone marrow suppression at least monthly. Consider therapy modification

Natalizumab: Immunosuppressants may enhance the adverse/toxic effect of Natalizumab. Specifically, the risk of concurrent infection may be increased. Avoid combination

Nivolumab: Immunosuppressants may diminish the therapeutic effect of Nivolumab. Management: Avoid use of immunosuppressants (including systemic corticosteroids) prior to initiation of nivolumab. Use of immunosuppressants after administration of nivolumab (eg, for immune-related toxicity) is unlikely to affect nivolumab efficacy. Consider therapy modification

Ocrelizumab: May enhance the immunosuppressive effect of Immunosuppressants. Monitor therapy

Ozanimod: Immunosuppressants may enhance the immunosuppressive effect of Ozanimod. Monitor therapy

Pidotimod: Immunosuppressants may diminish the therapeutic effect of Pidotimod. Monitor therapy

Pimecrolimus: May enhance the adverse/toxic effect of Immunosuppressants. Avoid combination

Roflumilast: May enhance the immunosuppressive effect of Immunosuppressants. Management: Consider avoiding concomitant use of roflumilast and immunosuppressants as recommended by the Canadian product monograph. Inhaled or short-term corticosteroids are unlikely to be problematic. Consider therapy modification

Siponimod: Immunosuppressants may enhance the immunosuppressive effect of Siponimod. Monitor therapy

Sipuleucel-T: Immunosuppressants may diminish the therapeutic effect of Sipuleucel-T. Management: Evaluate patients to see if it is medically appropriate to reduce or discontinue therapy with immunosuppressants prior to initiating sipuleucel-T therapy. Consider therapy modification

Smallpox and Monkeypox Vaccine (Live): Immunosuppressants may diminish the therapeutic effect of Smallpox and Monkeypox Vaccine (Live). Monitor therapy

Tacrolimus (Topical): May enhance the adverse/toxic effect of Immunosuppressants. Avoid combination

Tertomotide: Immunosuppressants may diminish the therapeutic effect of Tertomotide. Monitor therapy

Tofacitinib: Immunosuppressants may enhance the immunosuppressive effect of Tofacitinib. Management: Concurrent use with antirheumatic doses of methotrexate or nonbiologic disease modifying antirheumatic drugs (DMARDs) is permitted, and this warning seems particularly focused on more potent immunosuppressants. Consider therapy modification

Upadacitinib: Immunosuppressants may enhance the immunosuppressive effect of Upadacitinib. Management: Concomitant use of upadacitinib with potent immunosuppressants is not recommended. Drugs listed as exceptions to this monograph are discussed in separate drug interaction monographs. Avoid combination

Vaccines (Inactivated): Immunosuppressants may diminish the therapeutic effect of Vaccines (Inactivated). Management: Vaccine efficacy may be reduced. Complete all age-appropriate vaccinations at least 2 weeks prior to starting an immunosuppressant. If vaccinated during immunosuppressant therapy, revaccinate at least 3 months after immunosuppressant discontinuation. Consider therapy modification

Vaccines (Live): Immunosuppressants may enhance the adverse/toxic effect of Vaccines (Live). Immunosuppressants may diminish the therapeutic effect of Vaccines (Live). Management: Avoid use of live organism vaccines with immunosuppressants; live-attenuated vaccines should not be given for at least 3 months after immunosuppressants. Exceptions: Smallpox and Monkeypox Vaccine (Live). Avoid combination

Adverse Reactions

>10%:

Immunologic: Antibody development (3% to 12%; associated with reduced efficacy in psoriasis patients)

Infection: Infection (psoriasis: 27% to 72%; infection, severe: ≤3%)

Respiratory: Nasopharyngitis (11% to 24%)

1% to 10%:

Dermatologic: Acne vulgaris (Crohn disease: 1%), pruritus (2% to 4%)

Gastrointestinal: Abdominal pain (ulcerative colitis: 7%), dental disease (infection: 1%), diarrhea (ulcerative colitis: 4%), nausea (3%), vomiting (Crohn disease: 4%)

Genitourinary: Urinary tract infection (Crohn disease: 4%), vaginal mycosis (Crohn disease: ≤5%), vulvovaginal candidiasis (Crohn disease: ≤5%)

Hematologic & oncologic: Malignant neoplasm (excluding nonmelanoma: ≤2%), skin carcinoma (nonmelanoma including squamous cell carcinoma; psoriasis: 2%)

Infection: Influenza (ulcerative colitis: 6%)

Local: Erythema at injection site (1% to 5%)

Nervous system: Depression (psoriasis: 1%), dizziness (psoriasis: 2%), fatigue (3% to 4%), headache (5% to 10%)

Neuromuscular & skeletal: Arthralgia (psoriatic arthritis: 3%), asthenia (Crohn disease: 1%), back pain (psoriasis: 2%)

Respiratory: Bronchitis (Crohn disease: 5%), pharyngolaryngeal pain (psoriasis: 2%), sinusitis (3% to 4%)

Miscellaneous: Fever (ulcerative colitis: 5%)

<1%:

Dermatologic: Cellulitis

Gastrointestinal: Diverticulitis of the gastrointestinal tract

Hypersensitivity: Anaphylaxis

Infection: Herpes zoster infection

Local: Bleeding at injection site, bruising at injection site, induration at injection site, irritation at injection site, itching at injection site, pain at injection site, swelling at injection site

Nervous system: Meningitis due to listeria monocytogenes, reversible posterior leukoencephalopathy syndrome

Ophthalmic: Ocular herpes simplex

Frequency not defined:

Gastrointestinal: Appendicitis, cholecystitis, gastroenteritis

Genitourinary: Perirectal abscess

Infection: Sepsis, viral infection

Neuromuscular & skeletal: Osteomyelitis

Respiratory: Pneumonia

Postmarketing:

Dermatologic: Erythrodermic psoriasis, pustular psoriasis, skin rash, urticaria

Hypersensitivity: Angioedema, hypersensitivity reaction

Infection: Bacterial infection, fungal infection (including opportunistic)

Nervous system: Intracranial hypertension (Tan 2020)

Respiratory: Bronchiolitis obliterans organizing pneumonia, eosinophilic pneumonitis, interstitial pneumonitis, lower respiratory tract infection, tuberculosis

Warnings/Precautions

Concerns related to adverse effects:

• Antibody formation: Antibody formation to ustekinumab has been observed with therapy.

• Hypersensitivity reactions: Hypersensitivity, including anaphylaxis and angioedema, has been reported. Discontinue immediately with signs/symptoms of hypersensitivity reaction and treat appropriately as indicated.

• Infections: May increase the risk for infections or reactivation of latent infections. Serious bacterial, mycobacterial, fungal, and viral infections have been observed with use. Avoid use in patients with clinically important active infection until the infection resolves or is successfully treated. Exercise caution when considering use in patients with a history of new/recurrent infections, with conditions that predispose them to infections (eg, diabetes or residence/travel from areas of endemic mycoses), with chronic, latent, or localized infections, or who are genetically deficient in IL-12/IL-23 (IL-12/IL-23 genetic deficiency may predispose patients to disseminated infection). Patients who develop a new infection while undergoing treatment should consult their health care provider and be monitored closely. If a patient develops a serious infection, therapy should be discontinued or withheld until successful resolution of infection.

• Malignancy: May increase the risk for malignancy although the impact on the development and course of malignancies is not fully defined. Rapidly appearing cutaneous squamous cell carcinomas (multiple) have been reported in patients receiving ustekinumab who were at risk for developing nonmelanoma skin cancer. Monitor all patients closely for the development of nonmelanoma skin cancer; closely follow patients >60 years of age, with a history of prolonged immunosuppression, and in patients with a history of PUVA treatment. Use with caution in patients with prior malignancy (use not studied in this population).

• Neurotoxicity: Reversible posterior leukoencephalopathy syndrome (RPLS) has been observed (rare). RPLS symptoms include headache, seizures, confusion, and visual disturbances; may be fatal. Monitor; discontinue ustekinumab if symptoms occur and administer appropriate therapy.

• Noninfectious pneumonia: Cases of interstitial pneumonia, eosinophilic pneumonia, and cryptogenic organizing pneumonia, some leading to respiratory failure and prolonged hospitalization, have been reported; most commonly has occurred within the first few doses. Symptoms may include cough, dyspnea, and interstitial infiltrates. Discontinue therapy and institute appropriate treatment if noninfectious pneumonia is suspected or confirmed.

• Tuberculosis: Do not use in patients with active tuberculosis (TB). Patients should be evaluated for latent tuberculosis infection with a tuberculin skin test prior to starting therapy. Treatment of latent TB should be initiated before ustekinumab therapy is used. Consider antituberculosis treatment in patients with a history of latent or active tuberculosis if an adequate prior treatment course cannot be confirmed. During and following treatment, monitor for signs/symptoms of active TB.

Concurrent drug therapy issues:

• Allergen immunotherapy: Use caution in patients receiving or who have received allergen immunotherapy, particularly for anaphylaxis; ustekinumab may decrease the protective effect of allergen immunotherapy, which may increase the risk of an allergic reaction to allergen immunotherapy.

• Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.

• Immunosuppressive therapy: Use in combination with other immunosuppressive drugs during psoriasis studies has not been evaluated; use caution. Use in combination with methotrexate during psoriatic arthritis studies did not appear to affect safety or efficacy.

Special populations:

• Patients >100 kg: May require higher dose to achieve adequate serum levels.

Dosage form specific issues:

• Latex: Packaging may contain natural latex rubber.

• Polysorbate 80: Some dosage forms may contain polysorbate 80 (also known as Tweens). Hypersensitivity reactions, usually a delayed reaction, have been reported following exposure to pharmaceutical products containing polysorbate 80 in certain individuals (Isaksson 2002; Lucente 2000; Shelley 1995). Thrombocytopenia, ascites, pulmonary deterioration, and renal and hepatic failure have been reported in premature neonates after receiving parenteral products containing polysorbate 80 (Alade 1986; CDC 1984). See manufacturer's labeling.

Other warnings/precautions:

• Immunizations: Patients should be brought up to date with all immunizations before initiating therapy. Live vaccines should not be given concurrently; inactivated or nonlive vaccines may be given concurrently, but may not elicit a proper immune response. BCG vaccines should not be given 1 year prior to, during, or 1 year following treatment.

• Phototherapy: Use in combination with phototherapy has not been studied; use caution.

Monitoring Parameters

Tuberculosis screening (prior to initiating and periodically during therapy); CBC; ustekinumab-antibody formation; monitor for signs/symptoms of infection, reversible posterior leukoencephalopathy syndrome (RPLS), and squamous cell skin carcinoma.

Reproductive Considerations

The American Academy of Dermatology considers ustekinumab for the treatment of psoriasis to be acceptable for use in male patients planning to father a child (AAD-NPF [Menter 2019]).

Women and men with well-controlled psoriasis who are planning a pregnancy and wish to avoid fetal exposure can consider discontinuing ustekinumab 15 weeks prior to attempting pregnancy (Rademaker 2018).

Treatment algorithms are available for use of biologics in female patients with Crohn disease who are planning a pregnancy (Weizman 2019). When treatment for inflammatory bowel disease is needed, biologic therapy should be optimized prior to conception (Mahadevan 2019).

Pregnancy Considerations

Ustekinumab crosses the placenta (Klenske 2019; Rowan 2018).

Ustekinumab is a humanized monoclonal antibody (IgG1). Placental transfer of human IgG is dependent upon the IgG subclass, maternal serum concentrations, birth weight, and gestational age, generally increasing as pregnancy progresses. The lowest exposure would be expected during the period of organogenesis (Palmeira 2012; Pentsuk 2009).

Following administration to two pregnant patients with Crohn disease, cord blood concentrations of ustekinumab were ~2 to 4 times higher than maternal trough levels at delivery. In both cases, ustekinumab was administered throughout pregnancy and stopped 4 to 8 weeks prior to delivery (Klenske 2019; Rowan 2018). In one case, maternal trough concentrations remained stable throughout pregnancy (Rowan 2018).

Vaccination with live vaccines (eg, rotavirus vaccine) should be avoided for the first 6 months of life if exposure to a biologic agent occurs during the third trimester of pregnancy (eg, >27 weeks' gestation) (Mahadevan 2019).

The American Academy of Dermatology considers the safety of ustekinumab for the treatment of psoriasis in pregnancy to be uncertain (AAD-NPF [Menter 2019]).

Inflammatory bowel disease is associated with adverse pregnancy outcomes including an increased risk of miscarriage, premature delivery, delivery of a low birth weight infant, and poor maternal weight gain. Management of maternal disease should be optimized prior to pregnancy. Treatment decreases disease flares, disease activity, and the incidence of adverse pregnancy outcomes. Information related to the use of ustekinumab in pregnancy is limited. When treatment for inflammatory bowel disease is needed in pregnant women, appropriate biologic therapy can be continued without interruption. Serum levels should be evaluated prior to conception and optimized to avoid subtherapeutic concentrations or high levels which may increase placental transfer. Dosing can be adjusted so delivery occurs at the lowest serum concentration. For ustekinumab, the final injection can be given 6 to 10 weeks prior to the estimated date of delivery (4 to 5 weeks before delivery if every-4-week dosing), then continued 48 hours' postpartum (Mahadevan 2019).

Patient Education

What is this drug used for?

• It is used to treat plaque psoriasis.

• It is used to treat psoriatic arthritis.

• It is used to treat Crohn disease.

• It is used to treat ulcerative colitis.

All drugs may cause side effects. However, many people have no side effects or only have minor side effects. Call your doctor or get medical help if any of these side effects or any other side effects bother you or do not go away:

• Loss of strength and energy

• Nose irritation

• Nausea

• Headache

• Abdominal pain

• Diarrhea

• Vomiting

• Common cold symptoms

• Injection site irritation

• Throat irritation

WARNING/CAUTION: Even though it may be rare, some people may have very bad and sometimes deadly side effects when taking a drug. Tell your doctor or get medical help right away if you have any of the following signs or symptoms that may be related to a very bad side effect:

• Infection

• Urinary tract infection like blood in the urine, burning or painful urination, passing a lot of urine, fever, lower abdominal pain, or pelvic pain.

• Posterior reversible encephalopathy syndrome like confusion, not alert, vision changes, seizures, or severe headache.

• Shortness of breath

• Warm, red, or painful skin or sores

• Flushing

• Chest pain

• Cough

• Severe dizziness

• Passing out

• Vaginal pain, itching, and discharge

• Trouble breathing

• Skin lump

• Mole changes

• Skin growths

• Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing, swallowing, or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.

Note: This is not a comprehensive list of all side effects. Talk to your doctor if you have questions.

Consumer Information Use and Disclaimer: This information should not be used to decide whether or not to take this medicine or any other medicine. Only the healthcare provider has the knowledge and training to decide which medicines are right for a specific patient. This information does not endorse any medicine as safe, effective, or approved for treating any patient or health condition. This is only a limited summary of general information about the medicine's uses from the patient education leaflet and is not intended to be comprehensive. This limited summary does NOT include all information available about the possible uses, directions, warnings, precautions, interactions, adverse effects, or risks that may apply to this medicine. This information is not intended to provide medical advice, diagnosis or treatment and does not replace information you receive from the healthcare provider. For a more detailed summary of information about the risks and benefits of using this medicine, please speak with your healthcare provider and review the entire patient education leaflet.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Related questions